Show notes
OpenAI announced on October 20, 2026 that it had acquired Orchestra Bio and folded it into Rosalind, its life sciences tools. This flagship episode argues that owning the process only matters if it moves the verdict: better kill, continue, or submit decisions backed by evidence that survives regulatory scrutiny. OpenAI does not own the verdict today, and this episode lays out the checklist that would prove a verdict claim, from a published kill that saved a Phase 3 to a validated tool in a pivotal submission.Follow Forefront on X: https://x.com/Forefrontshow_Instagram…
Website: podcasters.spotify.com

